Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ferlay, J. et al Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359 (2015).
Arnold, M. et al. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am. J. Gastroenterol. 112, 1247–1255 (2017).
Zeng, H. et al Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries. Thorac. Cancer 7, 232 (2016).
Napier, K. J., Scheerer, M. & Misra, S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J. Gastrointest. Oncol. 6, 112 (2014).
Ma, K., Cao, B. & Guo, M. The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin. Epigenetics 8, 1–9 (2016).
Chen, K. et al Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 26, 103 (2016).
Vasanthakumar, A. & Godley, L. A. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. 208, 167–77 (2015).
Song, C. et al. 5-hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 27, 1231–42 (2017).
Li, W., Xu, Z. & Lu, X. 5-hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 27, 1243–57 (2017).
Han, D. L. et al A highly sensitive and robust method for genome-wide 5hmC profiling of rare cell populations. Mol. Cell. 63, 711 (2016).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Chen, T. & Guestrin, C. XGBoost: a scalable tree boosting system. In: Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, CA, USA. 785–794 (ACM, New York, NY, 2016).
Acknowledgements
This work was supported by the National Key R&D Program of China 2016YFC0900300, NSFC 31670895/U1504831/31741074, Major Science and Technology Project of Henan Province (161100310100), CAS Strategic Priority Research Program XDA16010108/XDB14030300, CAS Hundred Talent Program, Youth Innovation Promotion Association, CAS 2016097. Shanghai Epican Genetech sponsor part of the sequencing cost.
Author information
Authors and Affiliations
Contributions
Q.K., Y.-G.Y., and C.H. conceived the idea. X.T., J.Z., X.L., Z.Q., X.Z., Y.X., R.L., X.L. Y.-G.Y., and Q.K. design the experiments, recruited patients, collected blood and organized clinical information. Shanghai Epican Genetech finished all the hmC-Seal experiments with their protocol. C.C., C.G., B.S., L.W., and X.H. perform bioinformatics analysis under the supervision of D.H. B.S., C.C., C.G., J.Z., D.H. and Y.-G.Y. wrote the manuscript with input from all authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Tian, X., Sun, B., Chen, C. et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. Cell Res 28, 597–600 (2018). https://doi.org/10.1038/s41422-018-0014-x
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41422-018-0014-x
This article is cited by
-
5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation
Biomarker Research (2025)
-
cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma
World Journal of Surgical Oncology (2025)
-
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion
Biomarker Research (2025)
-
Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease
Cardiovascular Diabetology (2025)
-
Development of a deep learning model for cancer diagnosis by inspecting cell-free DNA end-motifs
npj Precision Oncology (2024)
